Efficacy of the combination of rituximab-bendamustine as a second-line treatment in patients with follicular lymphoma who progress after immunochemotherapy: a phase II trial of the Spanish Lymphoma Oncology Group

MeSH terms

• Adult
• Aged
• Aged, 80 and over
• Antineoplastic Combined Chemotherapy Protocols / administration & dosage*
• Antineoplastic Combined Chemotherapy Protocols / adverse effects
• Bendamustine Hydrochloride / administration & dosage*
• Bendamustine Hydrochloride / adverse effects
• Disease Progression
• Drug Administration Schedule
• Female
• Follow-Up Studies
• Humans
• Kaplan-Meier Estimate
• Lymphoma, Follicular / drug therapy*
• Lymphoma, Follicular / mortality
• Lymphoma, Follicular / pathology
• Maintenance Chemotherapy / methods
• Male
• Middle Aged
• Progression-Free Survival
• Prospective Studies
• Remission Induction / methods
• Rituximab / administration & dosage*
• Rituximab / adverse effects
• Spain / epidemiology